
    
      Patients aged ≥18 years, fulfilling the 2010 ACR EULAR criteria for RA (symptom duration less
      than two years) , having more than 4 joints involved & having moderate to severe disease
      activity (DAS28≥3.2) will be invited to participate. After providing written informed
      consent, eligible patients will be first started on MTX monotherapy & only patients who have
      persistant moderate disease activity (DAS28 ESR > 3.2) will be randomized into two groups.
      Block randomization will be done to generate random allocation sequence

      Group 1 - will receive MTX+LEF+HCQ Group 2- will receive MTX+SSZ+HCQ

      DMARD dosages used are: MTX 25 mg/week orally (dosage after 6 weeks),SSZ 2g/d (after 4 weeks)
      LEF 20 mg/day (dosage after 2 weeks) and HCQ 200 mg/day. Glucocorticoids will be given in an
      oral tapering scheme. All patients will be prescribed folic acid (10 mg/week) during MTX
      prescription.
    
  